Posted in | Pharmaceuticals and Drug Discovery

Key ADME and DMPK insights for oligonucleotide drug development

From Jun 20 2025

This on-demand webinar shares practical insights from real-world ADME and DMPK studies with oligonucleotide molecules, highlighting the unique challenges and considerations that come with working in this growing therapeutic space.

Topics covered:

  • Introduction to oligonucleotide bioanalysis
    • Understanding PK properties of oligos and strategies to influence distribution
    • Metabolism and excretion: how 2nd and 3rd generation oligos are cleared
  • Radiosynthesis of oligos
    • Available options and key considerations
  • Conducting radiolabeled nonclinical ADME studies
    • Practical tips and real-world examples

About the speakers

  • Steve Hood – Senior Scientific Director in Non-Clinical Sciences at GSK
  • Thomas Gregson​ – Tritium Team Leader at Pharmaron
  • Stephen Harris​ – Biologics Team Leader at Pharmaron​
  • Moderated by Chris Bode, Ph.D. – VP of Scientific Affairs at Pharmaron

Other Webinars from Pharmaron

Key considerations for dosimetry from non clinical to clinical application

Key considerations for dosimetry from non clinical to clinical application
Scaling up API production: How to balance speed with supply chain security

Scaling up API production: How to balance speed with supply chain security
The principles of macrocyclic drug discovery

The principles of macrocyclic drug discovery
Smarter drug design with molecular glues

Smarter drug design with molecular glues
Exploring CK1 degrader discovery and molecular glue technologies

Exploring CK1 degrader discovery and molecular glue technologies
Practical in vitro insights into low clearance compounds

Practical in vitro insights into low clearance compounds
Advancing hADME with modern AMS tools

Advancing hADME with modern AMS tools
Data-driven or physics-based: Choosing the smarter approach to DMPK modeling

Data-driven or physics-based: Choosing the smarter approach to DMPK modeling
What’s changing in DDI guidance? A closer look at ICH M12

What’s changing in DDI guidance? A closer look at ICH M12
Enhancing assay precision for small molecule bioanalysis

Enhancing assay precision for small molecule bioanalysis
Strategies for the successful development of antibody drug conjugates

Strategies for the successful development of antibody drug conjugates

Life Science Webinars by Subject Matter

Watch the
Webinar

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback